PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
| Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE
January 3, 2013 | ISSUE NUMBER 332 VOL 1

Special Feature
Best of the Blog: Pharm Exec’s 10 Most Read Stories of 2013
Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. Looking back on 2013, here are the 10 most-read stories published on PharmExec’s blog during the year, in case you missed them ...Read more

Social Media
Pharm Exec Global Digest Social Media Special
In the latest issue of Pharm Exec Global Digest: Has Pharma Finally ‘Got’ Social Media? — Five Ways Advanced Social Intelligence Can Guide Pharma Strategy ­­— Preparing for Crisis in an ‘Always On’ Digital Word — and more ...Read more

ZS Associates – Should You Pay the GSK Way?
GSK has been in the news frequently over the past three years with respect to changes in its incentive compensation program.Should you consider a similar plan?

Employment Survey
Pharma Industry Optimism Outweighs Concerns for Job Security
Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed muted optimism despite stagnant employment options in Pharmaceutical Technology’s latest employment survey
...Read more

Global
Europe’s New Clinical Trial Rules: Questions Remains on Data Transparency
Although a broad compromise was reached in late December on the future shape of the European Union's clinical trials rules, there are still many details to be resolved – including on that perennial issue of data transparency, writes Peter O’ Donnell
...Read more

Outsourcing
The Climate Change in Outsourcing
Financial, political, and scientific developments that began 10 years ago may have only just begun to affect the bio/pharma contract services industry, writes Jim Miller
...Read more

//Agilis Biotherapeutics (New York, NY) named George S. Zorich as the company’s new Chief Executive Officer.//ImmunoGen, Inc. (Waltham, MA) appointed David Johnston as Chief Financial Officer.//Halozyme Therapeutics, Inc. (San Diego, CA) announced that Helen Torley will be joining as President and Chief Executive Officer on January 6.//Wendell Wierenga, Ph.D, was appointed to the Board of Directors of Ocera Therapeutics, Inc. (Palo Alto, CA).//

January 28–29, 2014: 11th Annual Pharmaceutical Compliance Congress
Washington, DC.


January 28–29, 2014: Real World Evidence
Philadelphia, PA.


March 5–7, 2014: 15th Patient Assistance and Access Programs
Baltimore, MD.


 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook
Follow Pharm Exec on Linkedin

 

Survey
What in your opinion poses the biggest threat to the industry over the next five years?

Click To Vote
 

Quick Links

FDA Push for TRF Therapies Will ‘Disrupt Pain Market’

Global Parkinson’s Disease Market to Drop by $0.5 Billion by 2019

GSK Doubles Down on COPD and Asthma